Scisparc LtdSubsidiary validates quantum sampling workflow on S&P 500 platform, advancing computational capabilities.

SciSparc announced that its subsidiary NeuroThera Labs has completed internal validation of a proprietary quantum sampling workflow for clinical trials data analysis. The workflow, which represents continuous probability distributions within a quantum computing framework, was developed and evaluated using a hybrid quantum-classical computing platform from an S&P 500 company. This validation supports a key component of NeuroThera's broader computational architecture and is expected to expand capabilities for analyzing large-scale clinical and biomedical datasets. The technology is being advanced through CliniQuantum, a quantum-focused initiative in which NeuroThera holds a 54.01% stake.
Scisparc LtdSubsidiary validates quantum sampling workflow on S&P 500 platform, advancing computational capabilities.
NeuroThera Labs completed internal validation of its proprietary quantum sampling workflow.
CliniQuantum is the quantum initiative advancing the validated technology; NeuroThera holds 54.01% stake.